We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PD-L1-positive

News List

Roche's Tecentriq gains expanded approval in US for PD-L1-positive, triple-negative breast cancer biospectrumasia
March 11, 2019
Roche's Genentech unit on Friday announced that the FDA granted accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy for use in adults with PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast ca
NICE recommends MSD's Keytruda for advanced PD-L1-positive lung cancer pharmafile
June 07, 2018
UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS for the treatment of previously untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adult patients.